Makiko Moriuchi

Publications (3)0 Total impact

• Source

  Available from: jsltr.org

  Article: Characteristics of CD5-positive splenic marginal zone lymphoma with leukemic manifestation ; clinical, flow cytometry, and histopathological findings of 11 cases.

  Minoru Kojima, Eriko Sato, Kazuo Oshimi, Takuhei Murase, Tadashi Koike, Sinichirou Tsunoda, Toshiharu Matsumoto, Kousuke Marutsuka, Daisuke Ogiya, Makiko Moriuchi, Mami Tokunaka, Yukie Yara Kikuti, Tomoki Kikuchi, Naoya Nakamura, Kiyoshi Ando
  [show abstract] [hide abstract]
  ABSTRACT: Splenic marginal zone lymphoma (SP-MZL) is a rare low-grade B-cell neoplasm that often shows leukemic manifestation. Less than 20% of cases of SP-MZL express CD5. We analyzed 11 cases of CD5-positive SP-MZL with leukemic manifestation. The clinical characteristics of these cases did not differ from those of CD5-negative SP-MZL. Flow cytometry revealed positive results as follows : CD3, 0/9 ; CD5, 11/11 ; CD10, 0/11 ; CD11c, 4/10, CD13, 5/11 ; CD19, 11/11 ; CD20, 10/11 ; CD21, 4/4 ; CD22, 7/7 ; CD23, 5/10 ; CD25, 8/11 ; FMC7, 5/7 ; κ type 6/9, and λ type 2/9. All 3 cases with monoclonal γ-globulinemia expressed CD13. Resected spleen exhibited a proliferation of neoplastic cells in white pulp in all 8 splenectomy patients and a marginal pattern was detected in 5 patients. Only 2 cases showed involvement of red pulp. Immunohistochemistry showed that the lymphoma cells were positive for CD5, CD20, and BCL-2 and negative for CD3, CD10, cyclin D1, BCL-6, and MUM-1 in all 11 cases. These results suggest that CD5-positive SP-MZL differs from B-cell chronic lymphocytic leukemia, that CD13 expression is found in about half of CD5-positive SP-MZL cases, and that CD5-positive SP-MZL may be related to memory B-cell neoplasm or plasma cell differentiation.
  Journal of Clinical and Experimental Hematopathology 01/2010; 50(2):107-12.
• Source

  Available from: u-tokai.ac.jp

  Article: Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.

  Makiko Moriuchi, Ken Ohmachi, Minoru Kojima, Kosuke Tsuboi, Yoshiaki Ogawa, Naoya Nakamura, Kiyoshi Ando
  [show abstract] [hide abstract]
  ABSTRACT: In some patients with multiple myeloma, extramedullary masses may be present at diagnosis or may develop during treatment. Recently, multiple myeloma has been treated using newer therapeutic regimens based on thalidomide and bortezomib. Using these drugs, positive responses to treatment, not found with conventional antineoplastic agents, have been reported along with an improvement in patient outcome. In the present study, we report on three patients with extramedullary masses associated with multiple myeloma. Although all three patients were treated with bortezomib, it was ineffective against the extramedullary masses and the clinical course of the disease differed between the three patients. We propose that the effects of bortezomib on extramedullary masses may differ from case to case and may not be evident in cases of severe disease. Also, the effects of bortezomib may not be evident in the case of myeloma cells that have left the bone marrow microenvironment, similar to thalidomide. In addition, resistance to bortezomib may manifest as extramedullary masses. (160 words in the body of abstract).
  The Tokai journal of experimental and clinical medicine 01/2010; 35(1):17-20.
• Source

  Available from: u-tokai.ac.jp

  Article: A case of essential thrombocythemia presenting with aortic thrombosis.

  Masayuki Oki, Makiko Moriuchi, Hiroshi Kawada, Yoshiaki Ogawa, Kiyoshi Ando
  [show abstract] [hide abstract]
  ABSTRACT: Essential thrombocythemia (ET) is a chronic myeloproliferative disorder characterized by thrombo-hemorrhagic complications. But aortic thrombus formation is not so common in the patients with ET at the initial diagnosis. We describe a 65-year-old woman with ET found to have a thoraco-abdominal aortic thrombosis and have splenic infarction, which were successfully treated with medical therapy alone. To our knowledge, only two cases were published with presenting large aortic thrombosis at the onset.
  The Tokai journal of experimental and clinical medicine 01/2008; 33(4):135-7.